Skip to main content

Vaccines for the 21st Century A Tool for Decisionmaking (2000) / Chapter Skim
Currently Skimming:

Appendix 13: Insulin-Dependent Diabetes Mellitus
Pages 233-238

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 233...
... Insulitis is an inflammatory infiltrate composed mainly of T lymphocytes which invade the cells of the pancreas. The fourth step is a transformation in the surface of the beta cells causing the activation of the autoimmune response.
Read the entire page →
From page 234...
... For the purposes of the calculations in this report, it was assumed that 70% of patients receive conventional treatment for IDDM and 30% receive intensive treatment. It is assumed that there are costs associated with the diagnostic and very early phase of treatment, with the disease management during the 20-year period that was assumed to be free of chronic, serious sequelae, and with the disease management during the second phase, as well as costs associated with serious complications.
Read the entire page →
From page 235...
... Table 4-1 summarizes vaccine development assumptions for all vaccines considered in this report. VACCINE PROGRAM CONSIDERATIONS Target Population For the purposes of the calculations in this report, it is assumed that the target population for this vaccine is all newly diagnosed cases of IDDM.
Read the entire page →
From page 236...
... 236 Cal a~ o o F~ C~ ·= ~ V C~ ·_ o ~ V ~ .~ 3 ._ C~ CO o V Ct V C~ C~ E~ '> ~ V o Cd ~ s~ Ce C~ o U
Read the entire page →
From page 238...
... Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $10.8 million for an IDDM vaccine. If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is -$14,500.
Read the entire page →

Key Terms

  • target population
  • diabetes mellitus
  • committee assumptions
  • using committee
  • vaccine development

  • including time
  • care costs
  • monetary costs
  • beta cells
  • vaccine strategy

  • summarizes vaccine
  • vaccines considered
  • disease management
  • costs incurred
  • qalys gained

  • committee assumed
  • severe hypoglycemia
  • qaly gained
  • renal disease
  • serious complications

  • program cost
  • intensive treatment
  • physician visits
  • development assumptions
  • ultimately leading

  • complications associated
  • conventional treatment
  • patients receive
  • neurologic evaluation
  • events ultimately


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.